NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
XBiotech Inc. XBIT
13 fiscal years on record · USD · FY2025 reported · SEC filings only
$-45.5M
$-40.2M
Growth
—
Revenue, FY2025 · full 13-year series below
Revenue $M
Net income $M
FY2023 · Revenue 0.0 · Net income -24.6
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2022 · Operating -860.1% · Net -820.4%
ROE
FY2025 · ROE -28.2%
Each USD of equity lost 28 cents this year.
The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · |
| Operating income $B | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.7 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | 0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.49 | −1.26 | −0.81 | −1.08 | −0.58 | −0.36 | 14.44 | −0.59 | −0.95 | −1.63 | −1.22 | −0.90 | −0.45 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | −0 | −431 | −0 | 0 | · | · | · | · | · | · |
| ROE % | −28.2 | −19.2 | −10.7 | −12.9 | −5.6 | −2.0 | 167.8 | −41.6 | −55.6 | −65.1 | −46.3 | −62.7 | −97.1 |
| Shares out B | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 56 reconciliationsAUDITED
Reconciled in 13 of 19 fiscal years. 39 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013